• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-K filed by Priveterra Acquisition Corp. II

    4/2/24 4:05:29 PM ET
    $PMGM
    Blank Checks
    Finance
    Get the next $PMGM alert in real time by email
    NT 10-K 1 tm241182d2_nt10k.htm NT 10-K

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 12b-25

     

     

    NOTIFICATION OF LATE FILING

     

    (Check One):   x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q
    ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR
       
        For Period Ended: December 31, 2023
       
        ¨ Transition Report on Form 10-K
        ¨ Transition Report on Form 20-F
        ¨ Transition Report on Form 11-K
        ¨ Transition Report on Form 10-K
       
        For the Transition Period Ended:

     

    Read Instructions (on back page) Before Preparing Form. Please Print or Type.
    NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION HAS VERIFIED ANY INFORMATION CONTAINED HEREIN.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

     

    PART I — REGISTRANT INFORMATION

     

    Full Name of Registrant: PRIVETERRA ACQUISITION CORP. II
    Former Name if Applicable: N/A
    Address of Principal Executive Office (Street and Number): 1 Park Place
    City, State and Zip Code: Irvine, CA 92614

     

     

     

     

     

    PART II — RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed (Check box if appropriate)

     

    x   (a)   The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
      (b)   The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
      (c)   The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III — NARRATIVE

     

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    The Registrant is unable to file its Form 10-K for the year ended December 31, 2023 within the prescribed time period without unreasonable effort or expense due to an administrative delay that the Registrant experienced, necessitating additional time for compliance with the Registrant’s internal controls and procedures and a review of certain aspects of the Registrant’s financial statements and corresponding notes for inclusion in the Form 10-K. The Registrant anticipates that it will file its Form 10-K within the fifteen-day grace period provided by Rule 12b-25 of the Securities Exchange Act of 1934, as amended.

     

    PART IV — OTHER INFORMATION

     

    (1)   Name and telephone number of person to contact in regard to this notification:
                 
        Oleg Grodnensky   +1   (949) 787-2910
        (Name)   (Area Code)   (Telephone Number)
         
    (2)   Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). x Yes ¨ No
         
         
    (3)   Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ¨ Yes x No
         
        If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

     

     

     

    PRIVETERRA ACQUISITION CORP. II

    (Name of Registrant as Specified in Charter)

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: April 2, 2024 By: /s/ Oleg Grodnensky
          Oleg Grodnensky
          Chief Executive Officer

     

     

     

    Get the next $PMGM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PMGM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PMGM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Priveterra Acquisition Corp. II Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

    Priveterra Acquisition Corp. II (NASDAQ:PMGMU, PMGM, PMGMW))) (the "Company") today announced that on April 29, 2024, the Company received a notice (the "10-K Notice") from the staff of the Nasdaq Listing Qualifications department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") stating that, because the Company had not yet filed its Annual Report on Form 10-K for the period ended December 31, 2023 (the "Form 10-K"), the Company is not in compliance with Nasdaq Listing Rules for continued listing and, accordingly, such delinquency may serve as a separate basis for the delisting of the Company's securities from Nasdaq. The 10-K Notice also states that the Nasdaq Hearings Panel (the "P

    5/3/24 5:30:00 PM ET
    $PMGM
    Blank Checks
    Finance

    AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update

    Common stock and warrants of combined company will be listed on the New York Stock Exchange American under the symbols AEON and AEON WS, respectively Phase 2 topline data with ABP-450 for the preventive treatment of episodic migraine is anticipated to readout this fall $50 million financing provides sufficient cash runway to fund operations beyond the anticipated Phase 2 data announcement this fall IRVINE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON, AEON WS))), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, annou

    7/24/23 7:00:00 AM ET
    $PMGM
    Blank Checks
    Finance

    Priveterra Acquisition Corp. Announces Completion of Business Combination with AEON Biopharma, Inc.

    Priveterra Acquisition Corp. (NASDAQ:PMGM) ("Priveterra"), a special purpose acquisition company led by Chairman & CEO, Robert Palmisano, along with President, Vikram Malik, and COO and CFO, Oleg Grodnensky, today announced the successful completion of its business combination (the "Business Combination") with AEON Biopharma, Inc. ("AEON"), a Phase 3 stage-ready biopharmaceutical company developing a proprietary neurotoxin with initial focus on preventive treatments for episodic and chronic migraines along with other debilitating medical conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230721427813/en/ The resulting co

    7/21/23 4:27:00 PM ET
    $PMGM
    Blank Checks
    Finance

    $PMGM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Thunen Shelley B

    4 - AEON Biopharma, Inc. (0001837607) (Issuer)

    8/16/23 4:07:20 PM ET
    $PMGM
    Blank Checks
    Finance

    SEC Form 4 filed by Palmisano Robert J

    4 - AEON Biopharma, Inc. (0001837607) (Issuer)

    8/16/23 4:06:36 PM ET
    $PMGM
    Blank Checks
    Finance

    SEC Form 4 filed by Fischer Jost

    4 - AEON Biopharma, Inc. (0001837607) (Issuer)

    8/16/23 4:06:04 PM ET
    $PMGM
    Blank Checks
    Finance

    $PMGM
    SEC Filings

    View All

    SEC Form NT 10-Q filed by Priveterra Acquisition Corp. II

    NT 10-Q - Priveterra Acquisition Corp. II (0001821606) (Filer)

    5/16/24 6:02:05 AM ET
    $PMGM
    Blank Checks
    Finance

    Priveterra Acquisition Corp. II filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    8-K - Priveterra Acquisition Corp. II (0001821606) (Filer)

    5/3/24 4:01:08 PM ET
    $PMGM
    Blank Checks
    Finance

    SEC Form NT 10-K filed by Priveterra Acquisition Corp. II

    NT 10-K - Priveterra Acquisition Corp. II (0001821606) (Filer)

    4/2/24 4:05:29 PM ET
    $PMGM
    Blank Checks
    Finance

    $PMGM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Priveterra Acquisition Corp. II

    SC 13G - AEON Biopharma, Inc. (0001837607) (Subject)

    2/14/24 1:46:36 PM ET
    $PMGM
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by Priveterra Acquisition Corp. II (Amendment)

    SC 13G/A - AEON Biopharma, Inc. (0001837607) (Subject)

    2/14/24 9:00:10 AM ET
    $PMGM
    Blank Checks
    Finance

    SEC Form SC 13D/A filed by Priveterra Acquisition Corp. (Amendment)

    SC 13D/A - AEON Biopharma, Inc. (0001837607) (Subject)

    8/22/23 4:37:53 PM ET
    $PMGM
    Blank Checks
    Finance